Bausch + Lomb logo

Bausch + Lomb(TSX) BLCO

Market CapCA$8.84BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-3%
5 YearN/A
1 Year+12%
1 Month-6%
CA$22.51
-9.01%
-2.23Today
Bausch + Lomb last closing stock price
MetricPriceDate
Last closeCAD 22.512026-10-13
Bausch + Lomb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.56%CAD 24.352026-10-06
1 month-5.66%CAD 23.862026-09-11
3 month-1.53%CAD 22.862026-07-15
Year to date-4.01%CAD 23.452025-12-31
1 year+11.88%CAD 20.122025-10-10
3 year+1.08%CAD 22.272023-10-13
Since inception-2.98%CAD 25.502022-05-06

Bausch + Lomb Financials at a Glance

Market Cap

CA$8.84BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.32B

Net Income (TTM)

-$170.81M

EPS (TTM)

-CA$0.67

P/E Ratio

-37.18

Dividend

CA$0.00

Beta (Volatility)

0.92 (Low)

Price

CA$22.51

Volume

6,367

Open

CA$23.10

Previous Close

CA$22.51

Daily Range

CA$22.44 - CA$23.19

52-Week Range

CA$20.25 - CA$25.70

Estimated Earnings Date

Oct 28, 2026

BLCO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bausch + Lomb

Bausch + Lomb Corporation is a global leader in eye health, delivering a wide range of products and services across the world. Founded in 1853 and headquartered in Vaughan, Canada, the company operates in three key areas: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical.

Products and Services
  • Extensive selection of contact lenses and lens care solutions
  • Proprietary and generic medications for ophthalmic conditions
  • Advanced surgical tools for cataract and retinal treatments
Growth Outlook
  • Revenue of CAD 1.39 billion in Q2 2026, showing strong demand
  • Gross profit margin of 58.1% in Q2 2026, indicating operational efficiency
  • Continued investment in R&D to drive innovation and market expansion
Financial Highlights
  • Net income of CAD -13.99 million in Q2 2026, reflecting ongoing challenges
  • Operating income of CAD 114.95 million in Q2 2026, showcasing operational strength
  • Current ratio of 1.55, indicating solid short-term financial health

Bausch + Lomb Corporation stands out in the medical instruments and supplies industry, focusing on eye health solutions. The company's diverse product offerings cater to a wide range of consumer needs, from daily contact lenses to advanced surgical instruments. Despite facing challenges reflected in recent net income figures, the operational income and gross profit margins suggest a resilient business model. The current ratio indicates a strong ability to meet short-term obligations, while ongoing investments in research and development position the company for future growth. Overall, Bausch + Lomb presents a compelling opportunity for investors interested in the healthcare sector.

AI Generated • Sep 26, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

13,000

CEO

Brenton L. Saunders, MBA

Website

www.bausch.com

Headquarters

Vaughan, ON L4K 4B4, CA

BLCO Financials

Key Financial Metrics (TTM)

Gross Margin

57.23%

Operating Margin

7.14%

Net Income Margin

-3.21%

Return on Equity

-2.67%

Return on Capital

1.59%

Return on Assets

-1.23%

Earnings Yield

-2.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$8.84BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

357.17M

Volume

6.37K

Avg. Volume

1.63K

Financials (TTM)

Gross Profit

$2.96B

Operating Income

$593.95M

EBITDA

$989.95M

Operating Cash Flow

$458.31M

Capital Expenditure

-$317.80M

Free Cash Flow

$140.50M

Cash & ST Invst.

$367.00M

Total Debt

$5.12B

Bausch + Lomb Performance Analysis

Bausch + Lomb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,905,383,9443.9%
20232023-12-31USD 5,595,802,15714.1%
20242024-12-31USD 6,563,485,94417.3%
20252025-12-31USD 7,127,568,9758.6%
Bausch + Lomb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.2%
Q42025-12-319.7%
Q12026-03-31-11.7%
Q22026-06-3012.3%
Bausch + Lomb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.02N/A
20232023-12-31USD -1.00N/A
20242024-12-31USD -1.2323.3%
20252025-12-31USD -1.4215.2%
Bausch + Lomb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3055.6%
Q42025-12-31-100.0%
Q12026-03-31-25.0%
Q22026-06-3080.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.39B

+9.0%

Gross Profit

$809.65M

+7.5%

Gross Margin

58.11%

N/A

Market Cap

CA$8.84BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$679.71K

N/A

Employees

13,000

N/A

Net Income

-$13.99M

+77.4%

EBITDA

$216.95M

+146.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$367.00M

+38.0%

Total Debt

$5.12B

+3.1%

Accounts Receivable

$1.16B

+7.0%

Inventory

$999.00M

-4.9%

Long Term Debt

$5.07B

+2.9%

Short Term Debt

$43.00M

+53.6%

Return on Assets

-1.23%

N/A

Return on Invested Capital

3.17%

N/A

Free Cash Flow

$82.00M

+251.9%

Operating Cash Flow

$153.00M

+337.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BHC.TOBausch Health Companies Inc.
CA$8.36-3.24%
CURA.TOCuraleaf Holdings, Inc.
CA$12.54-5.79%
WELL.TOWELL Health Technologies Corp.
CA$4.18+0.97%
TLRY.TOTilray Brands, Inc.
CA$4.64-7.75%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About BLCO

What is the current price of Bausch + Lomb?

Bausch + Lomb is trading at CA$22.51 per share.

What is the 52-week range for Bausch + Lomb?

Over the past 52 weeks, Bausch + Lomb has traded between CA$20.25 and CA$25.70.

How much debt does Bausch + Lomb have?

As of the most recent reporting period, Bausch + Lomb reported total debt of $7.26B.

How much cash does Bausch + Lomb have on hand?

Bausch + Lomb reported $536.29M in cash and cash equivalents in its most recent financial results.

What is Bausch + Lomb’s dividend yield?

Bausch + Lomb does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services